Your browser is no longer supported. Please, upgrade your browser.
LTRN Lantern Pharma Inc. daily Stock Chart
Lantern Pharma Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own24.60% Shs Outstand6.22M Perf Week-14.40%
Market Cap81.86M Forward P/E- EPS next Y-1.56 Insider Trans0.00% Shs Float4.53M Perf Month14.37%
Income-2.70M PEG- EPS next Q-0.35 Inst Own30.30% Short Float0.47% Perf Quarter25.73%
Sales- P/S- EPS this Y-40.60% Inst Trans- Short Ratio0.56 Perf Half Y-
Book/sh3.74 P/B4.40 EPS next Y-12.20% ROA- Target Price24.50 Perf Year-
Cash/sh4.79 P/C3.44 EPS next 5Y- ROE- 52W Range10.40 - 19.50 Perf YTD10.17%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.54% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low58.37% ATR1.64
Employees4 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)53.39 Volatility8.69% 11.89%
OptionableNo Debt/Eq0.01 EPS Q/Q-78.10% Profit Margin- Rel Volume2.27 Prev Close16.82
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume37.53K Price16.47
Recom1.50 SMA200.17% SMA5018.05% SMA20020.42% Volume85,245 Change-2.08%
Sep-11-20 11:46AM  
Sep-04-20 06:01PM  
Aug-27-20 07:55AM  
Aug-18-20 01:29PM  
Aug-14-20 02:25PM  
Aug-05-20 09:00AM  
Jul-30-20 06:57AM  
Jul-24-20 07:56AM  
Jul-20-20 07:55AM  
Jul-16-20 11:00AM  
Jun-29-20 08:45AM  
Jun-17-20 09:23AM  
Jun-15-20 03:53PM  
Jun-11-20 08:12AM  
Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.